Verastem Inc recorded a cumulative net loss of $-194 million during 12 month ending in the first quarter 2026.
The Healthcare sector has seen employees of 327 other companies achieving higher income per employee. While Verastem Inc 's total ranking has deteriorated compared to the previous quarter from 3323 to 3930.

What is Income per Employee Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Net Income per Employee▼

None ▼

Net Income per Employee▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

VSTM Net Income per Employee	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter
Y / Y Net Income Change	-	-	-	-	-
Net Income per Employee (TTM) $	-1,901,559	-2,053,637	-2,363,784	-1,632,892	-1,459,578
VSTM's Total Ranking	# 3930	# 3323	# 3311	# 2311	# 3553
Seq. Net Income Change	-	-	-	-	-

VSTM Company Profile >> Back to VSTM Efficiency Comparisons >> Compare VSTM Net Income per Employee to its Competitors

VSTM Net Income per Employee Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 328
Healthcare Sector	# 755
Overall Market	# 3930

Net Income per Employee Statistics
High	Average	Low
$ -357,255	$ -837,083	$ -2,363,784
(Dec 31 2016)		(Sep 30 2025)

News about Verastem Inc Income per employee

FDA Approval of AVMAPKI FAKZYNJA A Breakthrough in Treating KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer

In a significant milestone for oncology, Verastem Oncology has announced that the U.S. Food and Drug Administration (FDA) has granted approval for AVMAPKI FAKZYNJA, a combination therapy comprising vutometinib capsules and defactinib tablets. This marks the first-ever treatment specifically targeted at adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC), a condition characterized by limited effective treatment options prior to this approval. BackgroundKRAS mutations are a hallmark of various malignancies, and their presence is often linked with a poor prognosis. Low-grade serous ovarian cancer, though less common than other ovarian cancer subtypes, poses significant challenges in terms of treatment approaches. Traditional therapies have largely been ineffective for patients whose cancer recurs after standard systemic treatments. The Drug and Its Mechanism of ActionAVMAPKI FAKZYNJA COPACK combines two novel agents: vutometinib, a selective inhibitor of mutated KRAS, and defactinib, which targets the FAK (Focal Adhesion Kinase) signaling pathway involved in tumor growth and metastasis. This dual-action approach aims to disrupt the cancer cell signaling that fosters the survival and proliferation of KRAS-mutated tumors. The targeted nature of this therapy addresses a crucial need within the oncology community for effective treatments tailored to specific genetic mutations.

Companies with similar Income per Employee for 12 month ending Mar 31 2026, within Healthcare Sector

Income per Employee

Income 12 month ending Mar 31 2026

Number of Employees Mar 31 2026

Date modified: 2026-08-30T14:48:48+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.